American Society of Hematology. (2018).
FDA Approves Ravulizumab-cwvz for Paroxysmal Nocturnal Hemoglobinuria.
Retrieved from https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2018/fda-approves-ravulizumab-cwvz-for-paroxysmal-nocturnal-hemoglobinuria.
American Society of Hematology.
"FDA Approves Ravulizumab-cwvz for Paroxysmal Nocturnal Hemoglobinuria." Hematology.org.
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2018/fda-approves-ravulizumab-cwvz-for-paroxysmal-nocturnal-hemoglobinuria
(label-accessed April 16, 2024).
"American Society of Hematology."
FDA Approves Ravulizumab-cwvz for Paroxysmal Nocturnal Hemoglobinuria, 16 Apr. 2024 ,
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2018/fda-approves-ravulizumab-cwvz-for-paroxysmal-nocturnal-hemoglobinuria.
